Clinical Research Roadmap
Our clinical development programs span neurodevelopment, neurodegeneration, and neuro-oncology—validating Galectin-3 as a master regulator across the human lifespan.
Autism Spectrum Disorder (ASD)
Investigating the role of Gal-3 blockade in restoring homeostatic brain connectivity by addressing the microglial hyper-activation associated with ASD etiology.
Community-Partnered Research
Our ASD program is bolstered by a strategic partnership with a leading ASD Foundation. This collaboration ensures that our scientific roadmap remains aligned with the needs and insights of the patient community.
UCSF Collaboration
ONCOLOGY BREAKTHROUGH
Our partnership with UCSF explores the "Immune Shield" theory: Glioblastoma uses Gal-3 to evade the immune system. Neutralizing this shield may turn "cold" tumors "hot."
Glioblastoma (GBM)
Investigating TB006 as a potential therapeutic to disrupt the Galectin-3 mediated immunosuppressive environment in malignant glioma.
Disrupting T-Cell Exclusion
Gal-3 acts as a barrier to T-cell infiltration; TB006 aims to dismantle this biological wall.
Neuro-Oncology Catalyst
Validating the CNS penetration of TB006 in high-grade glioma environments.